ASCO 2015:SLC1A5与三阴性乳腺癌TNBC总生存有关

2015-06-07 MedSci MedSci原创

SLC1A5是恶性肿瘤中的一种中性氨基酸转运体,与肿瘤的侵袭转移等生物学行为高度相关。通过靶向干预SLC1A5的功能,能抑制肿瘤细胞生长和激活自吞噬,这可能会改善TNBC的生存,使患者受益。Anna Maria Affan医生通过回顾性队列研究评估TNBC患者的生存状态和SLC1A5的表达水平,探索两者的关系。构建直方图来定义SLC1A5 “高”与“低”的分数,以5作为平均截点。然后应用Kapla

SLC1A5是恶性肿瘤中的一种中性氨基酸转运体,与肿瘤的侵袭转移等生物学行为高度相关。通过靶向干预SLC1A5的功能,能抑制肿瘤细胞生长和激活自吞噬,这可能会改善TNBC的生存,使患者受益。Anna Maria Affan医生通过回顾性队列研究评估TNBC患者的生存状态和SLC1A5的表达水平,探索两者的关系。构建直方图来定义SLC1A5 “高”与“低”的分数,以5作为平均截点。然后应用Kaplan-Meier方法进行组间比较,确定研究队列的总体生存率(P=0.05),认为具有统计学意义。

研究共包括171例TNBC患者,中位数年龄为51岁,且在淋巴结阴性、阳性上具有相同分布。本研究中112例患者可提供生存信息和SLC1A5评分。结果表明, 高表达SLC1A5的患者生存预后较差(P=0.00189)。另外,80例接受化疗的TNBC患者中具有高表达SLC1A5的生存更差(P=0.0005)。研究还发现SLC1A5与CAIX(低氧引起的碳酸酐酶IX)之间存在明显相关性(P=0.0189)。这项研究表明SLCA15与肿瘤组织缺氧有关,在三阴乳腺癌患者中化疗效果差。研究强调评价蛋白参与细胞代谢和自吞噬的重要性,这也许可以帮助我们建立新的治疗方式与目标。SLCA15与 CAIX之间的高度相关意味着后者可能参与肿瘤组织缺氧,本研究需要更多的临床试验进一步验证。

此前也有研究发现SLC1A5与NSCLC有关

相关资料:

Hassanein M, Qian J, Hoeksema MD, Wang J, Jacobovitz M, Ji X, Harris FT, Harris BK, Boyd KL, Chen H, Eisenberg R, Massion PP.Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer. Int J Cancer. 2015 Mar 26. doi: 10.1002/ijc.29535

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1794114, encodeId=64e31e941144b, content=<a href='/topic/show?id=b9e41639289' target=_blank style='color:#2F92EE;'>#SLC1A5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16392, encryptionId=b9e41639289, topicName=SLC1A5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Mar 01 22:56:00 CST 2016, time=2016-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047935, encodeId=f636204e93503, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Tue Aug 04 08:56:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938498, encodeId=88e619384983d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Nov 02 22:56:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26692, encodeId=4d7a2669289, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:20:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458660, encodeId=532d1458660dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Jun 09 01:56:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26223, encodeId=508026223f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76c01627110, createdName=liliweini, createdTime=Sun Jun 07 16:43:00 CST 2015, time=2015-06-07, status=1, ipAttribution=)]
    2016-03-01 lixiao3326
  2. [GetPortalCommentsPageByObjectIdResponse(id=1794114, encodeId=64e31e941144b, content=<a href='/topic/show?id=b9e41639289' target=_blank style='color:#2F92EE;'>#SLC1A5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16392, encryptionId=b9e41639289, topicName=SLC1A5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Mar 01 22:56:00 CST 2016, time=2016-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047935, encodeId=f636204e93503, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Tue Aug 04 08:56:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938498, encodeId=88e619384983d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Nov 02 22:56:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26692, encodeId=4d7a2669289, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:20:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458660, encodeId=532d1458660dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Jun 09 01:56:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26223, encodeId=508026223f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76c01627110, createdName=liliweini, createdTime=Sun Jun 07 16:43:00 CST 2015, time=2015-06-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1794114, encodeId=64e31e941144b, content=<a href='/topic/show?id=b9e41639289' target=_blank style='color:#2F92EE;'>#SLC1A5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16392, encryptionId=b9e41639289, topicName=SLC1A5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Mar 01 22:56:00 CST 2016, time=2016-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047935, encodeId=f636204e93503, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Tue Aug 04 08:56:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938498, encodeId=88e619384983d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Nov 02 22:56:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26692, encodeId=4d7a2669289, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:20:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458660, encodeId=532d1458660dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Jun 09 01:56:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26223, encodeId=508026223f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76c01627110, createdName=liliweini, createdTime=Sun Jun 07 16:43:00 CST 2015, time=2015-06-07, status=1, ipAttribution=)]
    2015-11-02 quxin068
  4. [GetPortalCommentsPageByObjectIdResponse(id=1794114, encodeId=64e31e941144b, content=<a href='/topic/show?id=b9e41639289' target=_blank style='color:#2F92EE;'>#SLC1A5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16392, encryptionId=b9e41639289, topicName=SLC1A5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Mar 01 22:56:00 CST 2016, time=2016-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047935, encodeId=f636204e93503, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Tue Aug 04 08:56:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938498, encodeId=88e619384983d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Nov 02 22:56:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26692, encodeId=4d7a2669289, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:20:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458660, encodeId=532d1458660dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Jun 09 01:56:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26223, encodeId=508026223f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76c01627110, createdName=liliweini, createdTime=Sun Jun 07 16:43:00 CST 2015, time=2015-06-07, status=1, ipAttribution=)]
    2015-06-09 huaxipanxing

    看看

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1794114, encodeId=64e31e941144b, content=<a href='/topic/show?id=b9e41639289' target=_blank style='color:#2F92EE;'>#SLC1A5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16392, encryptionId=b9e41639289, topicName=SLC1A5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Mar 01 22:56:00 CST 2016, time=2016-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047935, encodeId=f636204e93503, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Tue Aug 04 08:56:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938498, encodeId=88e619384983d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Nov 02 22:56:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26692, encodeId=4d7a2669289, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:20:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458660, encodeId=532d1458660dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Jun 09 01:56:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26223, encodeId=508026223f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76c01627110, createdName=liliweini, createdTime=Sun Jun 07 16:43:00 CST 2015, time=2015-06-07, status=1, ipAttribution=)]
    2015-06-09 xlysu
  6. [GetPortalCommentsPageByObjectIdResponse(id=1794114, encodeId=64e31e941144b, content=<a href='/topic/show?id=b9e41639289' target=_blank style='color:#2F92EE;'>#SLC1A5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16392, encryptionId=b9e41639289, topicName=SLC1A5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Mar 01 22:56:00 CST 2016, time=2016-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047935, encodeId=f636204e93503, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Tue Aug 04 08:56:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938498, encodeId=88e619384983d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Nov 02 22:56:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26692, encodeId=4d7a2669289, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:20:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458660, encodeId=532d1458660dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Jun 09 01:56:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26223, encodeId=508026223f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76c01627110, createdName=liliweini, createdTime=Sun Jun 07 16:43:00 CST 2015, time=2015-06-07, status=1, ipAttribution=)]
    2015-06-07 liliweini

    学习了

    0

相关资讯

ASCO 2015:ASCO现任主席对癌症治疗下一个50年的展望

主席寄语: 就在1年前,我们共同庆祝了美国临床肿瘤学会(ASCO">ASCO)的50周年纪念日,回顾了我们已经取得的杰出成就和里程碑似的飞跃。今天,站在ASCO历史上第2个50年的起点,我们要开始思考10年、20年乃至30年后,癌症和癌症的防治会发生哪些变化。我们要如何在日渐积累的、庞大而繁杂的知识库中找到真正的“宝藏”,让癌症患者最终获益?   ——彼得·保尔·于(Peter

ASCO 2015:膀胱尿路上皮癌免疫治疗进展

  图 北京大学肿瘤医院肾癌黑色素瘤内科 盛锡楠 近十余年来晚期尿路上皮癌的治疗尚无重大突破,特别是二线治疗仍处于探索阶段,虽然不断尝试新型化疗药物以及靶向药物等,但仍无标准二线治疗。近一年来肿瘤免疫治疗的突破性进展给晚期尿路上皮癌的治疗带来了一些曙光。2014年ASCO">ASCO大会晚期尿路上皮癌的进展情况基本代表了目前现状,以拉帕替尼、Apatorsen为代表的靶

ASCO 2015:ASCO宣布两项精准医疗试验计划--TAPUR和NCI-MATCH

  Richard L. Schilsky教授6月1日,2015 ASCO年会新闻发布会宣布了TAPUR和NCI-MATCH两项临床研究计划,这两项研究将致力于扩展精准医疗的范畴。前瞻性非随机TAPUR临床试验将在包括晚期实体瘤、多发性骨髓瘤和B细胞霍奇金淋巴瘤等存在药物靶向基因组变异的多种类型癌症中,采集有关于市售癌症靶向药物抗肿瘤活性和毒性反应的信息。启动时TAPUR将评估由5家药企

ASCO 2015:肿瘤药物争夺战

伴随着美国临床肿瘤学会会议(ASCO)的召开,整个生物制药投资界的目光都聚焦于芝加哥。 风险资本家Bruce Booth用近5000份会议摘要做了一个简要的数据分析。Booth认为,“虽然不清楚今年有什么正面或负面的新闻,至少直到这周末结束,从会议摘要中做的简要数据分析可以看出,医药界的关注点非常集中”。 会议摘要中有90%出现了关键词“病人”、“癌症”,接近三分之二提到“治疗”或包含“

ASCO 2015:两项乳腺癌靶向治疗研究---CALGB 40503和NeoSpher研究

河南省肿瘤医院 河南省乳腺病诊疗中心 闫敏 发自 美国芝加哥研究1:评价贝伐珠单抗加来曲唑一线治疗激素受体阳性转移性乳腺癌的Ⅲ期临床研究(CALGB 40503)报告者:美国纽约纪念斯隆-凯特林癌症中心Maura N. Dickler摘要号:501背景:临床前研究表明,雌激素可在生理和病理条件下调节血管生成,乳腺肿瘤中血管内皮生长因子(VEGF)的高表达与降低内分泌治疗反应性相关,研究者开展了一项

ASCO 2015:于金明院士点评大会报告LBA4--全脑放疗可以显著改善脑转移癌控制

尽管在放射外科(SRS)后行全脑放疗(WBRT)可以显著改善脑转移癌控制,但是鉴于其在神经认知方面的风险,辅助WBRT的地位仍被质疑。这项由NCI赞助的多中心III期临床研究,再次评估了SRS基础上增加WBRT治疗1~3个脑转移癌的疗效,结果发现,增加WBRT导致患者认知功能(尤其是即时回忆、记忆和语言交流)的下降,且不改善总生存。因此建议,SRS治疗后密切监测应该是此类患者的治疗选择。为此中国医